Vera Therapeutics, Inc 10-Q for FY2026 Q3
Vera Therapeutics, Inc. (VERA)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
Vera Therapeutics, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Vera Therapeutics’ TRUTAKNA received FDA accelerated approval on July 7, 2026, for adults with primary IgAN at risk for progression; it generated $10.3 million in product revenue through September 30, 2026, while requesting full approval on November 3, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $10.28M
- compared with $0 a year earlier
- Net loss
- $93.71M
- compared with a net loss of $80.29M a year earlier
- Diluted EPS
- -$1.30
- compared with -$1.26 a year earlier